Telephone
61.2.8964.7401
Address
Level 9 Suite 901 109 Pitt Street Sydney, New South Wales (NSW) 2000
Description
Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company was founded by Geoff E. D. Brooke & David Keast on March 23, 1999 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.01 - 0.1
Trade Value (12mth)
AU$38,573.00
1 week
-1.23%
1 month
95.12%
YTD
286.23%
1 year
141.27%
All time high
0.84
EPS 3 yr Growth
21.300%
EBITDA Margin
N/A
Operating Cashflow
-$9m
Free Cash Flow Return
-49.40%
ROIC
-61.00%
Interest Coverage
-931.80
Quick Ratio
7.00
Shares on Issue (Fully Dilluted)
2339m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
25 July 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
24 July 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
22 July 24 |
ACW June 2024 quarterly activity report & Appendix 4C
×
ACW June 2024 quarterly activity report & Appendix 4C |
19 July 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
18 July 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
17 July 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
10 July 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
09 July 24 |
Results of Meeting
×
Results of Meeting |
05 July 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
04 July 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
02 July 24 |
ACW XanaCIDD depression trial results expected early August
×
ACW XanaCIDD depression trial results expected early August |
26 June 24 |
Positive Xanamem biomarker trial published in Jnl Alz Dis
×
Positive Xanamem biomarker trial published in Jnl Alz Dis |
17 June 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
07 June 24 |
Appendix 3Ys x 5
×
Appendix 3Ys x 5 |
07 June 24 |
Letter to Shareholders, Notice of GM & Proxy Form
×
Letter to Shareholders, Notice of GM & Proxy Form |
05 June 24 |
ACW Oversubscribed $3.9 million entitlement offer completed
×
ACW Oversubscribed $3.9 million entitlement offer completed |
05 June 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
05 June 24 |
Notification regarding unquoted securities - ACW
×
Notification regarding unquoted securities - ACW |
03 June 24 |
ACW poster presentation at ADRF conference 2024
×
ACW poster presentation at ADRF conference 2024 |
30 May 24 |
Actinogen entitlement offer closed and oversubscribed
×
Actinogen entitlement offer closed and oversubscribed |
23 May 24 |
ACW Clinical Trials Science Forum slides & registration
×
ACW Clinical Trials Science Forum slides & registration |
16 May 24 |
Change in substantial holding
×
Change in substantial holding |
15 May 24 |
ACWs $3.9m entitlement offer opens & letters distribute
×
ACWs $3.9m entitlement offer opens & letters distribute |
14 May 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
14 May 24 |
Cleansing Notice
×
Cleansing Notice |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.